Chemomab Therapeutics Ltd. financial data

Symbol
CMMB on Nasdaq
Location
Kiryat Atidim, Building 7, Tel Aviv, Israel
Fiscal year end
December 31
Latest financial report
6-K - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 583 % -70.7%
Debt-to-equity 20.2 % +264%
Return On Equity -101 % -209%
Return On Assets -84.2 % -172%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 377M shares +32.7%
Common Stock, Shares, Outstanding 414M shares +44.1%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 286M shares +29.1%
Weighted Average Number of Shares Outstanding, Diluted 286M shares +29.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.93M USD -41.7%
General and Administrative Expense 840K USD -73.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.63M USD +54.2%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -2.06M USD +43.3%
Earnings Per Share, Basic 0.01 USD/shares -55.6%
Earnings Per Share, Diluted 0.01 USD/shares -55.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.45M USD +8.18%
Cash, Cash Equivalents, and Short-term Investments 9.5M USD
Assets, Current 10.6M USD -21.1%
Property, Plant and Equipment, Net 217K USD -21.4%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 11.1M USD -23.5%
Employee-related Liabilities, Current 386K USD -28.5%
Accrued Liabilities, Current 666K USD -73.8%
Liabilities, Current 1.43M USD -66.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.43M USD -68.6%
Retained Earnings (Accumulated Deficit) -108M USD -12.3%
Stockholders' Equity Attributable to Parent 9.7M USD -2.86%
Liabilities and Equity 11.1M USD -23.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.19M USD -93.6%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 14.4M USD +506%
Common Stock, Shares Authorized 4.65B shares 0%
Common Stock, Shares, Issued 414M shares +44.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.25M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.6M USD +9.51%
Deferred Tax Assets, Valuation Allowance 44.2M USD +1.72%
Deferred Tax Assets, Gross 44.2M USD +1.72%
Operating Lease, Liability 324K USD -17.3%
Depreciation 16K USD +23.1%
Payments to Acquire Property, Plant, and Equipment 1K USD -92.9%
Lessee, Operating Lease, Liability, to be Paid 346K USD -25.4%
Property, Plant and Equipment, Gross 529K USD 0%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 120K USD +4.35%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 22K USD -69.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 120K USD -0.83%
Deferred Tax Assets, Operating Loss Carryforwards 40.8M USD +6.53%
Lessee, Operating Lease, Liability, to be Paid, Year Four 106K USD -12.4%
Additional Paid in Capital 118M USD +10.9%
Deferred Tax Assets, Net of Valuation Allowance 0 USD